2020 global drug sales TOP100

Text | Pick up Bay

According to the product sales data disclosed in the 2020 financial reports of various pharmaceutical companies, there are 150 blockbuster drugs with global sales of more than 1 billion U.

2020 global drug sales TOP100 (100 million U.

In terms of drug types, 52 small-molecule drugs in the TOP100 drugs account for 46% of sales revenue.

Distribution of TOP100 drug types in 2020 (quantity, sales revenue)

From the field of disease, tumors, infectious diseases, immunity, endocrine, cardiovascular, and neurological diseases of the TOP100 drugs are the five largest markets, each exceeding US$20 billion.

Distribution of TOP100 pharmaceutical diseases in 2020 (quantity, sales revenue)

From a corporate perspective, Roche has the largest number of products among the TOP100 drugs, reaching 11, which is why Roche's pharmaceutical business volume can be ranked as the global champion in 2020.

Distribution of TOP100 pharmaceutical companies in 2020

In terms of specific varieties, the TOP1 throne still belongs to the "king of medicine" Humira.

Compared to 2019, several new faces have appeared in this year’s list, including Roche’s ADC drug Kadcyla (enmetrastuzumab), which is composed of trastuzumab that targets HER2 and inhibitory microbes.

Kadcyla sales over the years

Another drug worthy of attention is the bispecific antibody Hemlibra (Eimexizumab) for the treatment of hemophilia, which is still from Roche.

Another "dark horse" class drug is Trikafta (elexacaftor/tezacaftor/ivacaftor) from Vertex for the treatment of cystic fibrosis (CF).

In addition, AbbVie IL-23 monoclonal antibody Skyrizi (risankizumab) has been approved in Japan, the European Union, and the United States in March 2019, and has been approved for 4 indications in just over a year, each for the treatment of plaques Psoriasis, psoriatic arthritis, generalized pustular psoriasis, and erythroderma-type psoriasis will double their sales in 2020, reaching US$1.